Presbyopia is caused by a stiffening in the lens of the eye that develops in people after the age of 40, and affects an estimated 128 million people in the US. AbbVie is recommending Vuity ...

The FDA has approved the first and so far only pharmacological treatment for presbyopia, a sight condition that typically starts in middle age and involves difficulty in focusing on near objects ...

Presbyopia is an age-related refractive condition marked by a gradual decline in near vision, typically emerging between ages ...

The global myopia and presbyopia treatment market is set to expand by $9.76b from 2024 to 2028, with a compound annual growth rate (CAGR) of 9.05%, according to Technavio.

As men reach their 40s ageing can impact vision Regular eye check-ups and healthy habits are key to preventing common eye ...

Shares of LENZ Therapeutics jumped after the company said the Phase 3 trial of its presbyopia treatment in China met its primary endpoint for improving visual acuity. Presbyopia refers to the loss ...

LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on developing the first and only aceclidine-based eye drop to improve near vision in people with presbyopia. In this China ...

The recent approval of Vuity by the Food and Drug Administration marks a significant advancement in treating presbyopia, a common age-related condition that causes blurry vision. Local ...

New Drug Application (NDA) for LNZ100 for treatment of presbyopia accepted for review by the U.S. Food and Drug ...

The launch of emerging therapies, such as LNZ100 by Lenz Therapeutics, Phentolamine Ophthalmic Solution 0.75% by Viatris and Ocuphire Pharma, BRIMOCHOL PF (VT-1011) by Visus Therapeutics, among ...